HDAC6 inhibitor

0 marketed 2 in Phase 2

This page covers all HDAC6 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HDAC6.

Targets

Phase 2 pipeline (2)

GSK2269557 · GlaxoSmithKline · Oncology
GSK2269557 is a selective inhibitor of the histone deacetylase 6 (HDAC6).
CG400549 · CrystalGenomics, Inc. · Oncology, Neurology
CG400549 is a selective inhibitor of histone deacetylase 6 (HDAC6) that promotes the degradation of misfolded proteins and modulates immune responses.